ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
ProQR Therapeutics's total debt was €5.02M at Jun 30, 2026. For fiscal 2025 it was €4.87M, up 6.3% from the year before. The highest annual figure on record is €44.09M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €4.87M | +6.3% |
| FY2024 | Dec 31, 2024 | €4.58M | +6.8% |
| FY2023 | Dec 31, 2023 | €4.29M | -36.6% |
| FY2022 | Dec 31, 2022 | €6.77M | -84.6% |
| FY2021 | Dec 31, 2021 | €44.09M | +138.9% |
| FY2020 | Dec 31, 2020 | €18.46M | +41.4% |
| FY2019 | Dec 31, 2019 | €13.05M | +39.1% |
| FY2018 | Dec 31, 2018 | €9.39M | +29.6% |
| FY2017 | Dec 31, 2017 | €7.24M | +27.2% |
| FY2016 | Dec 31, 2016 | €5.70M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €5.02M | +6.1% |
| Q1 FY2026 | Mar 31, 2026 | €4.95M | +6.2% |
| Q4 FY2025 | Dec 31, 2025 | €4.87M | +6.3% |
| Q3 FY2025 | Sep 30, 2025 | €4.80M | +6.4% |
| Q2 FY2025 | Jun 30, 2025 | €4.73M | +6.5% |
| Q1 FY2025 | Mar 31, 2025 | €4.66M | +6.6% |
| Q4 FY2024 | Dec 31, 2024 | €4.58M | +6.8% |
| Q3 FY2024 | Sep 30, 2024 | €4.51M | -13.8% |
| Q2 FY2024 | Jun 30, 2024 | €4.44M | -31.7% |
| Q1 FY2024 | Mar 31, 2024 | €4.37M | -32.6% |
| Q4 FY2023 | Dec 31, 2023 | €4.29M | -36.6% |
| Q3 FY2023 | Sep 30, 2023 | €5.24M | -21.4% |
| Q2 FY2023 | Jun 30, 2023 | €6.50M | -85.6% |
| Q1 FY2023 | Mar 31, 2023 | €6.48M | -85.5% |
| Q4 FY2022 | Dec 31, 2022 | €6.77M | -84.6% |
| Q3 FY2022 | Sep 30, 2022 | €6.66M | -65.5% |
| Q2 FY2022 | Jun 30, 2022 | €44.99M | +142.7% |
| Q1 FY2022 | Mar 31, 2022 | €44.76M | +142.5% |
| Q4 FY2021 | Dec 31, 2021 | €44.09M | +151.6% |
| Q3 FY2021 | Sep 30, 2021 | €19.30M | +247.5% |
| Q2 FY2021 | Jun 30, 2021 | €18.53M | +35.8% |
| Q4 FY2020 | Dec 31, 2020 | €18.46M | +41.4% |
| Q3 FY2020 | Sep 30, 2020 | €17.53M | +62.7% |
| Q2 FY2020 | Jun 30, 2020 | €5.56M | -47.3% |
| Q1 FY2020 | Mar 31, 2020 | €13.65M | +45.4% |
| Q4 FY2019 | Dec 31, 2019 | €13.05M | +62.7% |
| Q3 FY2019 | Sep 30, 2019 | €10.77M | +48.7% |
| Q2 FY2019 | Jun 30, 2019 | €10.54M | +84.9% |
| Q4 FY2018 | Dec 31, 2018 | €9.39M | – |
| Q2 FY2018 | Jun 30, 2018 | €8.02M | – |
| Q4 FY2017 | Dec 31, 2017 | €7.24M | – |
| Q4 FY2016 | Dec 31, 2016 | €5.70M | – |
See a number that looks wrong?